Torrent Pharmaceuticals Ltd Stock Price Today (NSE: TORNTPHARM)
Fundamental Score
Torrent Pharmaceuticals Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis
Torrent Pharmaceuticals Ltd share price today is ₹5122.80, up +5.01% on NSE/BSE as of 31 July 2026. Torrent Pharmaceuticals Ltd (TORNTPHARM) is a Large-cap company in the Pharmaceuticals sector with a market capitalisation of ₹1.70L (Cr). The 52-week high for TORNTPHARM share price is ₹5140.70 and the 52-week low is ₹3480.60. At a P/E ratio of 77.52x, TORNTPHARM is currently trading above its industry average P/E of 34.89x. The company has a Return on Equity (ROE) of 27.43% and a debt-to-equity ratio of 1.79.
Torrent Pharmaceuticals Ltd Share Price Chart — NSE/BSE Historical Performance
Torrent Pharmaceuticals Ltd share price chart: 10.39% return over the past month. 52-week high ₹5140.70, 52-week low ₹3480.60.
Torrent Pharmaceuticals Ltd — Last 10 Trading Days
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| ₹4948.00 | ₹5140.70 | ₹4894.40 | ₹5122.80 | 14.28L (Cr) | |
| ₹4881.50 | ₹4949.00 | ₹4857.20 | ₹4878.50 | 7.77L (Cr) | |
| ₹5020.10 | ₹5040.00 | ₹4866.00 | ₹4898.30 | 5.49L (Cr) | |
| ₹4985.00 | ₹5070.00 | ₹4961.80 | ₹5019.50 | 2.68L (Cr) | |
| ₹4978.40 | ₹5050.00 | ₹4948.00 | ₹5040.70 | 2.88L (Cr) | |
| ₹4750.00 | ₹5030.00 | ₹4735.10 | ₹5005.40 | 9.59L (Cr) | |
| ₹4915.40 | ₹4932.90 | ₹4695.10 | ₹4763.00 | 13.97L (Cr) | |
| ₹5025.30 | ₹5085.80 | ₹4812.20 | ₹4987.60 | 50.61L (Cr) | |
| ₹4940.00 | ₹5010.00 | ₹4916.40 | ₹4973.50 | 7.94L (Cr) | |
| ₹4898.70 | ₹4973.00 | ₹4861.50 | ₹4951.10 | 7.64L (Cr) |
Torrent Pharmaceuticals Ltd — Last 12 Months Price History
| Month | Open | High | Low | Close | Change |
|---|---|---|---|---|---|
| ₹4646.90 | ₹5140.70 | ₹4574.30 | ₹5122.80 | +10.24% | |
| ₹4438.10 | ₹4742.90 | ₹4240.30 | ₹4620.10 | +4.10% | |
| ₹4185.10 | ₹4712.90 | ₹4185.10 | ₹4410.80 | +5.39% | |
| ₹4277.60 | ₹4333.00 | ₹3871.10 | ₹4185.10 | -2.16% | |
| ₹4191.00 | ₹4482.90 | ₹4161.20 | ₹4220.20 | +0.70% | |
| ₹4018.50 | ₹4470.00 | ₹3903.90 | ₹4333.30 | +7.83% | |
| ₹3860.00 | ₹4107.20 | ₹3695.00 | ₹3960.80 | +2.61% | |
| ₹3723.90 | ₹3863.00 | ₹3688.80 | ₹3850.00 | +3.39% | |
| ₹3560.10 | ₹3882.20 | ₹3532.60 | ₹3720.60 | +4.51% | |
| ₹3603.10 | ₹3685.60 | ₹3480.60 | ₹3560.10 | -1.19% | |
| ₹3569.40 | ₹3689.20 | ₹3483.10 | ₹3603.20 | +0.95% | |
| ₹3658.30 | ₹3700.00 | ₹3490.20 | ₹3559.80 | -2.69% |
Returns & Performance
Return on Equity (ROE)
Profit generated per ₹1 of shareholder equity
Return on Capital (ROCE)
Returns generated on total capital deployed
Oper. Profit Margin (5Y Avg)
Average operating profit margin over 5 years
Dividend Yield
Annual dividend as % of current share price
Torrent Pharmaceuticals Ltd Valuation Check
Price to Earnings (P/E)
Share price ÷ earnings per share. Lower = cheaper
Industry Avg P/E
Average P/E of all peers in this sector
Market Capitalisation
Total market value of all outstanding shares
Growth Engine
Profit Growth (Quarterly YoY)
Net profit growth vs same quarter last year
Revenue Growth (Quarterly YoY)
Revenue growth vs same quarter last year
Revenue Growth (5-Year CAGR)
Compounded annual revenue growth over 5 years
EPS Growth (5-Year CAGR)
Earnings per share growth over 5 years
Net Profit Growth (5-Year CAGR)
Compounded annual net profit growth over 5 years
Balance Sheet Health
Debt to Equity Ratio
Total debt ÷ equity. Below 0.5 = financially healthy
Interest Coverage Ratio
EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably
Free Cash Flow (5-Year Total)
Cash left after capex over 5 years. Positive = self-funded growth
Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice
Torrent Pharmaceuticals Ltd Fundamental Analysis & Valuation Benchmarking
Educational evaluation of TORNTPHARM across key market metrics for learning purposes.
Positive Indicators
9 factors identified
Strong Return on Equity (27.43%)
Observation: Efficient use of shareholders' capital generating superior returns.
Analysis: ROE >15% indicates strong profitability and effective management. This metric suggests the company can generate substantial returns on invested capital.
Excellent ROCE Performance (15.19%)
Observation: Superior returns on capital employed across business operations.
Analysis: ROCE >15% demonstrates efficient capital deployment and strong operational performance.
Strong Operating Margins (31.13%)
Observation: Healthy 5-year operating margins indicate pricing power and cost control.
Analysis: OPM >15% suggests operational efficiency and competitive advantages.
Strong Revenue Growth (41.84%)
Observation: Healthy sales growth indicates market demand and execution capability.
Analysis: Revenue growth >15% suggests strong market position and growth potential.
Strong Interest Coverage (8.56x)
Observation: Earnings comfortably cover interest obligations.
Analysis: Interest coverage >5x indicates low financial distress risk.
Strong Cash Generation (₹10904.35 Cr over 5Y)
Observation: Healthy free cash flow generation supports growth and returns.
Analysis: Strong FCF provides flexibility for dividends, debt reduction, and growth investments.
Balanced Promoter Holding (68.31%)
Observation: Optimal balance between promoter control and public float.
Analysis: Promoter holding in 50-75% range provides management alignment.
Strong Institutional Confidence (FII+DII: 25.14%)
Observation: Significant professional investor participation.
Analysis: High institutional holding often signals thorough due diligence.
Zero Share Pledging Risk
Observation: No promoter shares pledged as collateral.
Analysis: Absence of share pledging eliminates potential forced-selling pressure.
Risk Factors
3 factors identified
Premium Valuation Risk (P/E: 77.52x)
Observation: High valuation multiples may limit upside potential.
Analysis: Elevated P/E ratios require strong growth execution to justify current valuations.
Profit Decline Concern (-20.58%)
Observation: Significant year-over-year profit contraction observed.
Analysis: Declining profitability requires investigation into underlying causes.
Elevated Debt Levels (D/E: 1.79)
Observation: High leverage increases financial risk and interest burden.
Analysis: High debt-to-equity ratios require monitoring of debt servicing capability.
Torrent Pharmaceuticals Ltd vs Pharmaceuticals Peers
Peer Comparison - Pharmaceuticals
Compare Torrent Pharmaceuticals Ltd with 10 other companies in the same sector
| Company Info | Fundamental | Valuation | Profitability | Financial Health | Growth | Dividend | ||||
|---|---|---|---|---|---|---|---|---|---|---|
Company Company name | Score Bull Run comprehensive fundamental score based on 20+ metrics | Price Current trading price of the stock | Market Cap Total value of all shares in the market | P/E Price per share divided by earnings per share | ROE Net income divided by shareholder equity | ROCE Earnings before interest and tax divided by capital employed | Debt/Eq Total debt divided by total equity | Profit 5Y Average annual profit growth over 5 years | Sales 5Y Average annual sales growth over 5 years | Dividend Annual dividend per share divided by price per share |
Torrent Pharmaceuticals LtdTorrent Pharmac...Selected✓ TORNTPHARM • 500420 | 51.4/100 | ₹5122.80₹5123 | ₹169902.02₹169902.02 | 77.52Average 77.5 Average | 27.43%Excellent 27.43% Excellent | 15.19%Good 15.19% Good | 1.79Average 1.8 Average | 12.07%Good 12.07% Good | 11.80%Good 11.80% Good | 0.76% |
Sun Pharmaceutical Industries LtdSun Pharmaceuti... SUNPHARMA • 524715 | 66.4/100 | ₹1990.50₹1991 | ₹468821.49₹468821.49 | 37.73Average 37.7 Average | 15.95%Good 15.95% Good | 20.53%Excellent 20.53% Excellent | 0.06Excellent 0.1 Excellent | 16.75%Excellent 16.75% Excellent | 11.78%Good 11.78% Good | 0.82% |
Divis Laboratories LtdDivis Laborator... DIVISLAB • 532488 | 56.3/100 | ₹8056.00₹8056 | ₹193163.97₹193163.97 | 73.64Average 73.6 Average | 16.53%Good 16.53% Good | 21.96%Excellent 21.96% Excellent | 0.00Excellent 0.0 Excellent | 5.71%Good 5.71% Good | 8.67%Good 8.67% Good | 0.41% |
Cipla LtdCipla Ltd... CIPLA • 500087 | 40.2/100 | ₹1473.20₹1473 | ₹116131.81₹116131.81 | 30.51Average 30.5 Average | 11.60%Average 11.60% Average | 15.49%Good 15.49% Good | 0.02Excellent 0.0 Excellent | 9.94%Good 9.94% Good | 8.01%Good 8.01% Good | 0.90% |
Zydus Lifesciences LtdZydus Lifescien... ZYDUSLIFE • 532321 | 74.1/100 | ₹1078.30₹1078 | ₹115375.77₹115375.77 | 21.26Average 21.3 Average | 21.25%Excellent 21.25% Excellent | 21.14%Excellent 21.14% Excellent | 0.46Excellent 0.5 Excellent | 18.77%Excellent 18.77% Excellent | 12.45%Good 12.45% Good | 0.09% |
Lupin LtdLupin Ltd... LUPIN • 500257 | 83.4/100 | ₹2415.00₹2415 | ₹113976.53₹113976.53 | 20.04Average 20.0 Average | 28.68%Excellent 28.68% Excellent | 29.93%Excellent 29.93% Excellent | 0.29Excellent 0.3 Excellent | 37.02%Excellent 37.02% Excellent | 13.02%Good 13.02% Good | 0.72% |
Mankind Pharma LtdMankind Pharma ... MANKIND • 543904 | 61.5/100 | ₹2469.60₹2470 | ₹105053.91₹105053.91 | 52.29Average 52.3 Average | 13.12%Average 13.12% Average | 13.50%Average 13.50% Average | 0.39Excellent 0.4 Excellent | 10.52%Good 10.52% Good | 18.10%Excellent 18.10% Excellent | 0.04% |
Dr Reddys Laboratories LtdDr Reddys Labor... DRREDDY • 500124 | 41/100 | ₹1148.10₹1148 | ₹102660.46₹102660.46 | 25.62Average 25.6 Average | 11.22%Average 11.22% Average | 13.04%Average 13.04% Average | 0.20Excellent 0.2 Excellent | 15.44%Excellent 15.44% Excellent | 12.09%Good 12.09% Good | 0.65% |
Aurobindo Pharma LtdAurobindo Pharm... AUROPHARMA • 524804 | 24.6/100 | ₹1580.20₹1580 | ₹90035.87₹90035.87 | 25.38Average 25.4 Average | 10.06%Average 10.06% Average | 12.80%Average 12.80% Average | 0.21Excellent 0.2 Excellent | 0.80%Average 0.80% Average | 6.32%Good 6.32% Good | 0.26% |
Laurus Labs LtdLaurus Labs Ltd... LAURUSLABS • 540222 | 34.1/100 | ₹1816.20₹1816 | ₹84016.75₹84016.75 | 93.94Average 93.9 Average | 18.30%Good 18.30% Good | 17.76%Good 17.76% Good | 0.48Excellent 0.5 Excellent | -1.89%Poor -1.89% Poor | 7.19%Good 7.19% Good | 0.13% |
Biocon LtdBiocon Ltd... BIOCON • 532523 | 30.2/100 | ₹425.70₹426 | ₹70826.50₹70826.50 | 181.85Average 181.8 Average | 1.40%Poor 1.40% Poor | 3.75%Poor 3.75% Poor | 0.45Excellent 0.5 Excellent | -11.84%Poor -11.84% Poor | 18.83%Excellent 18.83% Excellent | 0.12% |
Top Pharmaceuticals Stocks
View all →By Bull Run Score
By Return on Equity
By Market Cap
- Sun Pharmaceutical Industries Ltd share price468821.49 Cr
- Divis Laboratories Ltd share price193163.97 Cr
- Cipla Ltd share price116131.81 Cr
- Zydus Lifesciences Ltd share price115375.77 Cr
- Lupin Ltd share price113976.53 Cr
Torrent Pharmaceuticals Ltd PE Ratio History
Historical price-to-earnings ratio for TORNTPHARM — last 5 years
| Year | EPS (₹) | Price (₹) | P/E Ratio |
|---|---|---|---|
| FY 2025 | ₹56.47 | ₹3850.00 | 68.2x |
| FY 2024 | ₹48.94 | ₹3360.05 | 68.7x |
| FY 2023 | ₹36.79 | ₹2305.55 | 62.7x |
| FY 2022 | ₹22.96 | ₹1550.60 | 67.5x |
P/E = year-end price ÷ diluted EPS from annual filings. Source: NSE/BSE via Bull Run.
Torrent Pharmaceuticals Ltd Dividend History
Annual cash dividends paid by TORNTPHARM — dividend yield 0.76%
| Financial Year | Dividends Paid (₹ Cr) |
|---|---|
| FY 2025 | ₹1083.03 Cr |
| FY 2024 | ₹1015.34 Cr |
| FY 2023 | ₹863.04 Cr |
| FY 2022 | ₹676.89 Cr |
Cash dividends from annual cash flow statements. Past dividends do not guarantee future payments. Not investment advice.
Torrent Pharmaceuticals Ltd Quarterly Performance
Latest quarterly metrics for TORNTPHARM — revenue growth and profit growth vs same quarter last year
Revenue Growth (YoY)
41.84%
Latest quarter vs same quarter previous year
Net Profit Growth (YoY)
-20.58%
Latest quarter net profit vs same quarter previous year
5-Year Revenue CAGR
11.80%
Compounded annual revenue growth over 5 years
5-Year Profit CAGR
12.07%
Compounded annual net profit growth over 5 years
Torrent Pharmaceuticals Ltd Technical Indicators
SMA 50, SMA 200, RSI and volume signals for TORNTPHARM — calculated from daily price history
Momentum is balanced — neither overbought nor oversold.
Technical indicators are for educational purposes only. Not investment advice.
Torrent Pharmaceuticals Ltd Financial Statements
Annual income statement, balance sheet and cash flow for Torrent Pharmaceuticals Ltd (TORNTPHARM) — sourced from NSE/BSE filings.
Loading Financial Statements...
Fetching financial data for Torrent Pharmaceuticals Ltd
About TORNTPHARM (Torrent Pharmaceuticals Ltd)
Torrent Pharmaceuticals Ltd is a global pharmaceutical powerhouse driven by a relentless pursuit of innovation and a deep commitment to improving patient lives. They operate on a f...oundation of robust research and development, crafting both branded and generic formulations that address a spectrum of medical needs. From the bustling laboratories where new treatments are conceived to the advanced manufacturing facilities where they are brought to life, Torrent Pharmaceutical's commitment to quality and efficacy is evident. Their dedication extends beyond simply creating medicine; it encompasses a global network of distribution channels, ensuring their products reach those who need them most across diverse international markets. The company's therapeutic scope is broad, covering areas crucial to modern healthcare. They are key players in developing treatments for chronic conditions like diabetes and cardiovascular diseases, as well as tackling infectious diseases and managing pain. Their product portfolio extends to specialized fields such as oncology, neurology, and nephrology, showcasing their versatility and dedication to addressing complex medical challenges. Beyond their core therapeutic areas, Torrent Pharmaceuticals also recognizes the importance of overall well-being, offering solutions in areas like gynecology, dermatology, and gastrointestinal health. This multifaceted approach reflects a comprehensive understanding of the diverse needs of patients across the globe. Torrent Pharmaceuticals' global reach extends far beyond their Indian roots, with a significant presence in key markets like the United States, Brazil, and Germany. This international expansion is a testament to their ability to adapt to diverse regulatory landscapes and meet the unique demands of various healthcare systems. By forging strategic partnerships and investing in local infrastructure, Torrent Pharmaceuticals ensures its products are accessible and affordable to patients worldwide. Their commitment to global health is further underscored by their dedication to ethical practices and sustainable operations, positioning them as a responsible and trusted leader in the pharmaceutical industry.
Company Details
Key Leadership
Corporate Events
TORNTPHARM Share Price: Frequently Asked Questions
What is the current share price of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd (TORNTPHARM) trades at ₹5122.80 on NSE and BSE. Market cap ₹1.70L (Cr). Educational data only.
What is the P/E ratio of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a P/E of 77.52x vs industry average 34.89x.
What is the Bull Run score for Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has a Bull Run score of 51.4/100 based on 25+ financial parameters.
Does Torrent Pharmaceuticals Ltd pay dividends?
Torrent Pharmaceuticals Ltd has a dividend yield of 0.76%. Past dividends don't guarantee future payments.
What is the ROE of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has ROE of 27.43%. Higher ROE indicates better use of shareholder equity.
What is the debt-to-equity ratio of Torrent Pharmaceuticals Ltd?
Torrent Pharmaceuticals Ltd has debt-to-equity of 1.79.
Is Torrent Pharmaceuticals Ltd a good investment?
Bull Run gives Torrent Pharmaceuticals Ltd a score of 51.4/100. This is not investment advice — consult a SEBI-registered advisor.